Wednesday, November 26, 2014 9:36:06 AM
Is this a case where another larger company could simply fold apdn (once a workable field reader is commercialized) into its own operations and then offer the markers basically for free as more of a added-value service to help generate customer loyalty and enhance its own brand awareness?
I guess the question I'm asking is whether APDN's business model is doomed by its own success at being able to mass produce virtually costless markers, which can then be verified by customers out in the field? Where will the large revenue streams come from? The markers? The field testing chips/devices? And it's not as if there aren't other cost effective alternatives out in the market and perhaps emerging. I think the rationale for APDN's business model is coming under increasing scrutiny by investors.
Recent APDN News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 10:18:33 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:25:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/12/2024 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:01:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:05:28 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:24:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 10:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/07/2023 09:01:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 10:09:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2023 10:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:02:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 09:04:44 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM